Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336801 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24908854 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30090538 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24908457 | 0.88 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30322487 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24679063 | 0.79 | PIK3CA (0.53) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL30336136 | 0.77 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25532939 | 0.77 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25532166 | 0.77 | PIK3CA (0.49) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25532941 | 0.77 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |